Oral Vaccines Market Size, Share, Growth, and Industry Analysis, By Type (Rotavirus Vaccine, Cholera Vaccine, Oral Polio Vaccine), By Application (Public, Private) and Regional Forecast to 2035

ORAL VACCINES MARKET OVERVIEW

The global Oral Vaccines Market size estimated at USD 2807.08 million in 2026 and is projected to reach USD 3184.98 million by 2035, growing at a CAGR of 4.3% from 2026 to 2035.

The Oral Vaccines Market is one of the most promising segments of the global market for the biological in general, and vaccines in particular, due to the continuing development of biotechnology, the growth of vaccination coverage, and the search for ways to administer the drug other than parenteral. Tablet and drops form of vaccines, also known as oral vaccines have several benefits over their injectable counterparts due to the route of administration including; Accessibility, patient cooperation, and associated risks with needles. These vaccines are vital in the containment of communicable diseases, and more importantly in developing countries where there is little if any, health infrastructure. Today many diseases like polio, cholera and rotavirus have oral vaccines for treatment, thus have brought significant improvements to many countries. Other ongoing improvements in the research and development sector regarding oral vaccines for other diseases new-age threats like COVID-19 are expected to propel oral vaccine market growth in the future years.

• • 

    Request a Free sample to learn more about this report.

ORAL VACCINES MARKET KEY FINDINGS

• Market Size and Growth: The Oral Vaccines Market size was USD 2580.39 Million in 2024, is projected to grow to USD 2679.18 Million by 2025 and exceed USD 2927.77 Million by 2033, with a CAGR of 4.3%.

• Key Market Driver: Ease of administration is pushing oral vaccines into the spotlight—especially in low-resource settings. In fact, over 85 countries rely on oral polio vaccines for mass immunization campaigns due to their simplicity and scalability.

• Major Market Restraint: Stability in extreme environments remains a hurdle. Roughly 30% of vaccine loss in rural outreach programs is tied to temperature sensitivity, and oral formats aren't immune to that.

• Emerging Trends: Research on plant-based edible vaccines is no longer just theoretical. As of 2023, at least four candidates have entered early-stage human trials—imagine a future where immunity is delivered via a tomato or banana.

• Regional Leadership: Asia-Pacific continues to dominate demand, driven by large-scale immunization efforts. India alone accounted for nearly 36 million oral polio doses distributed in 2023, according to WHO data.

• Competitive Landscape: The market is relatively concentrated. Around 10 major players—including Merck, GlaxoSmithKline, and Bharat Biotech—control a significant chunk, with newer biotech entrants gaining traction in mucosal delivery innovations.

• Market Segmentation: Pediatric use remains the dominant segment, representing over 60% of global oral vaccine volume due to childhood immunization schedules. Adult use is growing but still niche.

• Recent Development: In 2024, Vaxart completed Phase II trials for its norovirus oral tablet vaccine, with reported efficacy exceeding 50%, a potentially game-changing leap in travel medicine and outbreak control.

GLOBAL CRISES IMPACTING ORAL VACCINES MARKET - COVID-19 IMPACT

"Oral Vaccines Market Had a Negative Effect Due to Supply Chain Disruption During COVID-19 Pandemic"

The Global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

COVID-19 pandemic has affected the Oral Vaccines Market share in various ways. Cut short in manufacturing and distribution, closure of healthcare facilities, and long lockdown restrictions were the major impacts of Covid-19 on vaccine development and reaching children through immunization, especially communities of developing nations. Campaigns for polio and cholera type diseases which were previously conducted regularly and were mass drills were rarely conducted during the year or almost completely abandoned with the consequence of reduced immunization and elevated risk of preventable diseases. Also, the impact of COVID-19 as a powerful focal point in the distribution of vaccination needs seems to have pulled out the attention of manufacturers and countries to COVID-19 vaccine production leaving other important types of vaccine such as oral vaccines behind. This was cyclical gestation and general pubic suspicion with vaccines in equal measure also contributing to low vaccine acceptability. All these factors combined to reign in the rate of growth of the Oral Vaccines Market during the pandemic.

LATEST TREND

"A Sustainable and Scalable Innovation Drives Market Growth"

One of the trends identified in the field of oral vaccines is the development of plant-based oral vaccines, which imply the utilization of genetically modified plants producing the client vaccine antigens. This strategy is more effective, efficient, safe and economical in comparison to the current methods of vaccine production. The plant-based vaccines can be taken systematically hence they are easily administrable as compared to those vaccines which needs to be introduced with the help of hypodermic syringes. This could revolutionize global vaccinations by decreasing the reliance on cold chain equipment and decreasing cost of production and increase from new diseases and pandemics.

• • 

    Request a Free sample to learn more about this report.

ORAL VACCINES MARKET SEGMENTATION

By Type

Based on type, the global market can be categorized into Rotavirus Vaccine, Cholera Vaccine, Oral Polio Vaccine

• rotavirus Vaccine: Works against rotavirus, which is a major reason for severe diarrhea in children below the age of five years. It is taken orally and has a very important role in saving child’s life through treatment of diarrheal dehydration.

• cholera Vaccine: Prevents incidence of cholera; an acute diarrheal disease that results from unsanitary water or food. The oral vaccine is utilized in outbreak-prone regions and for travelers to those regions.

• oral Polio Vaccine: Previously administered for poliomyelitis which is a highly infectious viral health condition that causes paralysis. OPV is mostly used in mass polio immunization campaigns, in countries that are physically campaigning to eliminate poliomyelitis.

By Application

Based on application, the global market can be categorized into Public, Private

• public: That is why; vaccines are administered through government funded immunization programs that afford or at most cost populations especially those from low income or high risk areas. Some population health interventions on the part of the public sector are concentrated on score coverage in the population for the prevention of epidemics.

• private: There are vaccines and shots can be bought from various health care centers, physicians and pharmacies to many inhabitants who choose to be immunized privately prior or instead of through governmental campaigns. The private sector targets individuals who want vaccines now or more if not covered under the government health programs.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.

Driving Factors

"Ease of Administration Boost the Market"

Oral Vaccines Market growth are not only easy to administer since they do not include needles but do not even need professional medical attendants. A main advantage of this procedure is that it is non-invasive was preferred by the patient as children and patients with needle phobia. It increases patient compliance, the safety of needle-related infections, and lowers healthcare expenses. Because oral vaccines reduce logistical and medical challenges to immunization, they increase the immunization coverage.

"Broader Immunization Access Expand the Market"

The features of the oral vaccines are less sensitive to temperature fluctuations, thus requiring less stringent shipping conditions. This makes them suitable for use in the rural / hard to reach areas, where cold chain can be a challenge. Oral vaccines can cover a larger population with immunizations since they are store and transported more easily than the injected vaccines. It is especially so in the low income countries, in the fight of ailments such as poliomyelitis and cholera and in an overall lift in health standards.

Restraining Factor

"Limited Stability in Harsh Environments Potentially Impede Market Growth"

One of the most important factors that act as a restraint in Oral Vaccines Market is its stability in severe circumstances. Despite the fact that some oral vaccines require lower temperatures than those used in injections, some formulations still have problems with low stability in extreme conditions, such as extremely high temperature or high humidity. To illustrate this, in environments that lack required facilities, for example remote or poorly developed, maintaining the stability of the vaccines is a challenge. This can be a massive problem when it comes to mass distribution and consequently diminishes the success rates of vaccination, most especially in the Third World countries.

Opportunity

"Rising Demand for Non-Invasive Vaccination Methods Create Opportunity for The Product in The Market"

One opportunity that is likely to be experienced in the Oral Vaccines Market is increasing demand of non-intramuscular vaccines. Given the increasing popularity of non-needle technologies that show patient preference for immunizations particularly children and those who have needle phobia, oral vaccines are favourable products. This trend is set to increase as more vaccines for diseases such as cholera, rotavirus, COVID 19 among others are being developed to favour oral delivery in compliance, access, and market cover.

Challenge

"Regulatory and Manufacturing Hurdles Could Be a Potential Challenge for Consumers"

One of the factors for consideration in the Oral Vaccines Market is the ability to steer clear of regulatory and manufacturing obstacles. Oral vaccines are still under high regulatory interest in terms of safety and efficacy, which may differ from one country to another this makes it even more challenging to launch on a global level. Further, mass production demands high sanitary centers that will be able to maintain the stability and efficacy of live or attenuated oral vaccines. To unlock the market growth, these challenges need to be addressed to ultimately ensure that oral vaccines are taken by larger population.

• • 

    Request a Free sampleto learn more about this report.

•  

ORAL VACCINES MARKET REGIONAL INSIGHTS

North America

North America especially United States Oral Vaccines Market holds a major market share in oral vaccines owing to it exposures towards biotechnology development and developed health care systems. This region is endowed with several big pharmaceutical companies and research institutions that are always in the process of developing other new vaccines. Widespread vaccination programs encouraged and sponsored by governments along with increasing importance of preventive medicine factor positively to the demand of oral vaccines. Moreover, a high incidence of conditions, such as rotavirus, and the existence of a developed health care system allow North America to maintain its leading position as a player which stimulates further development and consumption of oral vaccines.

Europe

In Europe the large extent of immunization programs accompanied by sound government support. The oral vaccines are convenient, especially for multiple doses, hence European nations are more interested in providing vaccination for children. The European Medicines Agency EMA guarantees that vaccines meet the highest quality, safety and efficacy requirements and thus encourages the society to embrace the use of vaccines. In addition, many European countries are active players in the development of vaccines, and more generally in the field of pharmaceutical sectors. Given efforts in neighboring areas to eradicate diseases like polio and cholera, the continent of Europe fortifies the impact on.

Asia

Increased population density and government sponsored vaccination programs are creating a steady growth in Asia for Oral Vaccines Market. Huge numbers of population in the countries like India and China are getting themselves immunized against the infectious diseases and this puts into demand oral vaccines. The populations in the region are diverse both in terms of immunization requirements and infrastructural constraints making oral vaccines viable in terms of cost and implementation. Also, the increasing development of biotechnological products in Asia and those collaborations and investments in research of the Europe and America will support the development of the market. From its geographical perspective, Asia plays crucial roles in meeting the fight against global health threats through mass immunization.

KEY INDUSTRY PLAYERS

"Key Industry Players Shaping the Market Through Innovation and Market Expansion"

The key industry players in Oral Vaccines Market are GlaxoSmithKline (GSK), Merck & Co., Pfizer Inc., Sanofi, and Bharat Biotech. Oral vaccines for rotavirus include GSK’s Rotarix and Merck’s RotaTeq while many more players in area include Pfizer and Sanofi who are developing different vaccine technologies. The new entrant ‘Vaxart’ along with another new generation entrant ‘PaxVax’ is a company that is focused toward oral vaccines for infectious diseases including COVID-19. This combination of leading pharmaceutical companies and Biotech companies promotes product development of oral vaccines and improves manufacturing capacity and global vaccination efforts making them key players in the Oral Vaccines Market.

List of Market Players Profiled

• Sanofi (France)
• Valneva (France)
• Serum Institute (India)
• PaxVax (U.S.)

KEY INDUSTRY DEVELOPMENT

April 2024: Recently, WHO prequalified a new, simpler and cheaper oral cholera vaccine, named Euvichol-S. This new vaccine is intended to improve production capability in order to help address the current severe inadequacies of vaccines during cholera epidemics.

REPORT COVERAGE

The Oral Vaccines Market will experience further expansion because of an increase in the utilization of non-IVR vaccination, high demand for non-invasive treatment provisions, and a higher coverage of immunization. Some of these prominent solution-providers are Sanofi, Valneva, and PaxVax that are working to create the best oral vaccines for humanity. The new vaccines’ WHO prequalification and partnerships that have been created with the purpose of increasing production capacities suggest the interest in increasing the efficacy of public health systems. Hence, challenges like; the need for compliance with regulatory requirement and added , stability for multioperation in the many environments persist. To overcome these challenges and extend the coverage of oral vaccines worldwide, it is necessary to eliminate barriers that exist between experienced pharma corporations and start-ups Biotech firms. Several continuous researches and development programs on the improvement and advancements suggest that there will be positive outlook of the Oral Vaccines Market in the future especially in the less developed countries.